Navigation Links
UL Expands Presence in Medical Device Market With Acquisition of MDT
Date:8/2/2011

NORTHBROOK, Ill. and OCHSENHAUSEN, Germany, Aug. 2, 2011 /PRNewswire/ -- UL, a world leader in advancing safety, today announced that it has acquired mdt medical device testing GmbH (MDT) and md registration support Ltd. (MDRS).  These two entities, based in Ochsenhausen, Germany, will become part of UL's Life and Health business unit.  

MDT is a leading accredited and GLP certified test laboratory for the medical services industry.  MDT specializes in clinical and non-clinical testing services for regulatory and routine control purposes.  Its testing services include clinical investigations as a clinical research organization (CRO) according to ISO 14155, and comprehensive non-clinical testing services such as physico-chemical and chemical analyses, physical testing, mechanical testing, biocompatibility testing, microbiological and virological testing, cytotoxicity testing and validation of cleaning, reprocessing, sterilization and packaging processes.  MDRS's advisory services enable customers to meet comprehensive medical device registration requirements through technical documentation, risk assessment, clinical evaluation, evaluation of biocompatibility, classification of medical devices and quality management assessment pursuant to EN ISO 9011 and EN ISO 13485, respectively.

UL will now offer a complete suite of services that will help medical device manufacturers produce safer devices and products, including key medical device testing.  The tests are conducted in laboratories that produce repeatable test results under and EN ISO/IEC 17205 and GLP/GCP quality management system, which will expose potential patient side effects well before the medical device is in the market.  The addition of MDT and MDRS will further support UL on a global scale to help medical device manufacturers obtain required medical device certification, including IEC 60601-X-X and ISO 10993-XX, as well as technical documentation services that enable medical device manufacturers to demonstrate product safety to regulatory authorities around the globe.

In an effort to meet the growing demands of the medical device market, the acquisition gives UL best-in-class global capabilities that will be offered to both its current customer base, and more notably, to a larger segment of medical device manufacturers, that perform critical health functions in the human body. This includes orthopedic, ophthalmic, and many cardiovascular implantable devices.  

"The deepening of our service offerings will put the UL brand in front of a wider variety of customers -- including some of the biggest companies in the medical and health field," said Anil Patel, General Manager of UL Health Sciences.  "From sterile gauze and bandages to more complex devices such as bone screws, contact lenses, orthopedic, dental and other implantable devices, UL's testing capabilities will help manufacturers develop products that will keep patients healthy and mobile."  

"MDT and UL share the vision of providing comprehensive clinical and non-clinical services, with the sole purpose of supporting manufacturers provide safe and effective medical devices to patients around the globe," said Dr. Dieter R. Dannhorn, CEO and President, MDT and MDRS.  "Together, we can provide a full spectrum of testing and consulting services necessary to help medical device companies develop and manufacture innovative medical devices and document safety and effectiveness of these products throughout the product's lifecycle."

MDT and MDRS will become part of UL's Life and Health business unit.  MDT and MDRS will continue to be headquartered in Ochsenhausen, Germany.  Dr. Dieter R. Dannhorn will remain with the companies and serve as the General Manager.  

About mdt medical device testing GmbH (MDT)

Founded in 1988, MDT is a privately-owned leading provider of clinical and non-clinical testing services for medical device manufacturers.  With approximately 40 employees, its headquarters are located in Ochsenhausen, Germany.  MDT is EN ISO/IEC 17025 accredited as a test laboratory and as a medical clinical research organization (CRO) for medical devices by the Central Authority of the Lander for Health Protection (Central Authority).  MDT is also GLP certified as a test facility for non-clinical services.  Additional information can be found at www.mdt-gmbh.com.

About md registration support Ltd. (MDRS)

Founded in 2005 in Ochsenhausen, Germany, md registration support Ltd. provides hands-on assistance for medical device manufacturers to comply with global regulations and requirements to obtain CE-marking of their devices. It helps clients prepare technical documentation, build quality management systems, establish risk management processes and to prepare clinical evaluations and biocompatibility assessments.  MDRS is EN ISO 9001 and 13485 certified to help start-up companies develop, establish and maintain regulatory registrations.  Additional information can be found at www.mdrs-ltd.com.

About UL

UL is a premier global independent safety science company with more than 116 years of history.  Employing more than 6,900 professionals in over 100 countries, UL has five distinct business units -- Product Safety, Environment, Life and Health, University, and Verification Services -- to meet the expanding needs of our customers and to deliver on our public safety mission.  Additional information about UL may be found at UL.com.


'/>"/>
SOURCE UL
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
3. Cellectar Expands Clinical Management Team
4. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
5. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
6. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
7. PAREXEL Expands Global Clinical Pharmacology Capabilities
8. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
9. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017 Research and ... Analysis and Strategies - 2016" report to their offering. ... The latest research ... data and benchmarks in the global Fibromyalgia market. The ... the key drugs marketed for Fibromyalgia and their clinical attributes? How ...
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... & Trends - Industry Forecast to 2025" report to their ... The ... around 6.9% over the next decade to reach approximately $47.6 billion ... estimates and forecasts for all the given segments on global as ...
(Date:2/23/2017)...  MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative ... to develop and market advanced products and therapies for ... and Dental sectors of healthcare, today announced its record ... December 31, 2016. Full Year 2016 Highlights ... increase over full year 2015 revenue ...
Breaking Medicine Technology:
(Date:2/23/2017)... Denver, Colorado (PRWEB) , ... February 23, 2017 ... ... Dialog Magazine, an exciting, new, interactive publication where generations converge and explore the ... to expand their worldview, Dialog Magazine enables readers to gain understanding, increase empathy, ...
(Date:2/23/2017)... ... (PRWEB) February 23, ... the nation to come together to combine its favorite springtime ... its favorite fruit – apples! To celebrate National Nutrition Month, ... the “Apple Madness” bracket tournament – a five-week, five-round online ...
(Date:2/23/2017)... ... 23, 2017 , ... Thomas Vas-Don suffered from severe injury due ... was able to successfully recover. In “ Origin & Insertion Charts for Massage Therapists ... the principals of massage, anatomy , trigger points and referral pain patterns ...
(Date:2/22/2017)... ... February 22, 2017 , ... Stem cell therapy has ... technology is so cutting edge, in fact, the U.S. Food and Drug Administration ... However, successful patient outcomes in certain clinical stem cell procedures have shown that ...
(Date:2/22/2017)... ... 2017 , ... Giving patients with diabetes customized coaching sessions, ... hospital admissions, and better blood pressure and glycemic control, a new study ... be found here . , The study comes as health plans increasingly ...
Breaking Medicine News(10 mins):